Hemab Therapeutics just made the biotech world sit up straighter, locking in an oversubscribed $157M Series C to take prevention mainstream in bleeding disorders medicine forgot. Cambridge, MA meets Copenhagen, DK in a company proving that anticipation, not reaction, builds both better health and better markets. When the science is tight, the story sells itself, data doesn’t lie, and Hemab’s numbers are talking loud.
Congrats to CEO & President Benny Sorensen, MD, PhD, the co-founding CFO & GM Mads Behrndt, MSc, CMO Kate Madigan, MD, COO Anant Murthy, PhD, SVP Cécile Bonvoisin, MSc, and SVP Tara O’Meara for setting the pace. With Chair of the Board John Maraganore, PhD, and Sofinnova Partners’ Joe Anderson, PhD, now joining the board, this leadership mix has the kind of clinical, commercial, and capital chemistry that doesn’t come together by chance. From 101 Main in Cambridge to Nordre Fasanvej in Copenhagen, Hemab’s footprint screams global ambition backed by local precision.
The investor roster reads like biotech’s A-list: Sofinnova Partners led, with Qatar Investment Authority, Avoro Capital Advisors, and a global asset manager joining forces with return players RA Capital, Novo Holdings, Access Biotechnology, Deep Track, HealthCap, Invus, Avoro Ventures, Maj Invest Equity & Rock Springs. That lineup isn’t chasing hype, it’s following proof.
And the proof’s in the clinic. Sutacimig (HMB-001) wrapped Phase 2 enrollment with 34 pts in Glanzmann thrombasthenia and showed more than 50% drop in median treated bleeds, from 21.2 to 4.61 events, no thromboses, no discontinuations. HMB-002 hit early signals too: 1x 20mg SC dose in VWD patients raised mean VWF more than 1.5x baseline within 14 days. Add Orphan Drug + ILAP designations and WHO’s 2025 nonproprietary nod, and the regulatory momentum is real.
GT360 & VWD360 flipped the understanding of disease burden: 117 GT participants showed 88% with severe bleed frequency, often 60-80 events/year; more than 600 VWD participants revealed that lab values don’t predict lived experience. This is where Hemab’s tech-agnostic model hits, using Genmab’s DuoBody bispecific to stabilize FVIIa & target TLT-1 on activated platelets, or a monovalent antibody to extend VWF & lift FVIII, all in long-acting SC formats that turn survival into living.
Market pull is clear. The VWD space hit approximately $565M in 2024, heading toward approximately $967M by 2035 at 5% CAGR, while GT, though ultra-rare, represents unserved, life-threatening need. With $347M total funding, Hemab’s Series C primes registration trials for sutacimig in 2026, pushes HMB-002 deeper into clinic, and tees up HMB-003 for 1H26. Novo Nordisk & Genmab tech, Maraganore’s blueprint, Murthy’s launch muscle, it’s all converging. The ultimate clotting company isn’t a tagline anymore. It’s the new circulation system for rare disease biotech.
